Gilead Sciences (GILD) Shares are Up 1.68%

Gilead Sciences (GILD) has been under a strong bear grip, hence the stock is down -6.77% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.71% in the past 1 week. The stock has risen by 1.68% in the past week indicating that the buyers are active at lower levels, but the stock is down -6.41% in the past 4 weeks.

Gilead Sciences Inc. has dropped 1.43% during the last 3-month period . Year-to-Date the stock performance stands at -19.11%. The stock has recorded a 20-day Moving Average of 0.23% and the 50-Day Moving Average is 2.24%.


Gilead Sciences (NASDAQ:GILD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $80.56 and $80.23 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $81.18. The buying momentum continued till the end and the stock did not give up its gains. It closed at $81.00, notching a gain of 0.51% for the day. The total traded volume was 8,227,939 . The stock had closed at $80.59 on the previous day.

Also, Argus Research downgrades its rating on Gilead Sciences (NASDAQ:GILD). Analysts at the Argus Research have a current rating of Hold on the shares. The shares were previously rated Buy. The rating by the firm was issued on July 29, 2016.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.